# Management of Stage I and Advanced Germ Cell Tumors
## Overview
Management of germ cell tumors involves careful surveillance protocols for stage I seminoma and non-seminoma, precise surgical techniques for retroperitoneal lymph node dissection (RPLND), and the use of cisplatin-based chemotherapy regimens. Indications for post-chemotherapy RPLND are also critical in advanced disease management.
---
## Stage I Seminoma Management
Surveillance is the preferred approach for stage I seminoma due to its favorable outcomes. The 5-year relapse rate under surveillance is approximately 15-20%, with most relapses occurring within the first two years and about 85% localized to the retroperitoneum. Despite this relapse risk, cancer-specific survival remains around 99%, as salvage chemotherapy is highly effective. The surveillance protocol includes serial CT scans of the abdomen and pelvis, tumor marker assessments, and clinical examinations. During the first two years, CT imaging is performed every six months, followed by annual scans from years three to five, totaling about seven to eight CT scans over five years to balance relapse detection with radiation exposure. Tumor size greater than 4 cm and rete testis invasion have been identified as risk factors for relapse, although their utility in guiding management decisions remains controversial. Current guidelines from the AUA and NCCN recommend surveillance as the preferred management for all patients with stage I seminoma, regardless of these risk factors.
An alternative to surveillance is adjuvant carboplatin chemotherapy, typically administered as a single cycle at an area under the curve (AUC) of 7. The SWENOTECA trial demonstrated that this approach reduces relapse rates to 3-5%. Advantages of adjuvant carboplatin include its simplicity, good tolerability, and single infusion administration. However, it carries some risk of long-term toxicity and may be unnecessary for most patients. It is generally considered for patients who have concerns about compliance with surveillance or experience significant anxiety.
Historically, adjuvant radiation therapy was widely used, involving para-aortic strip radiation at doses of 20-26 Gy. This approach achieved relapse rates under 5%, but it has largely been abandoned due to the risk of late secondary malignancies, including gastrointestinal and hematologic cancers, as well as cardiovascular toxicity. Current AUA and NCCN guidelines do not recommend radiation as standard care for stage I seminoma.
---
## Stage I Non-Seminoma (NSGCT) Management
For stage I non-seminomatous germ cell tumors (NSGCT), surveillance is preferred for patients with pathological stage pT1 tumors without lymphovascular invasion (LVI). The overall 5-year relapse rate is 15-20%, but it decreases to 10-15% in the absence of LVI. Surveillance protocols involve CT scans of the abdomen and pelvis, chest X-rays, and tumor marker assessments every two to three months for the first two years, followed by less frequent monitoring. Cancer-specific survival reaches 99% with prompt salvage treatment upon relapse. Relapses predominantly occur in the retroperitoneum (60-70%), with 20-30% presenting in the lungs or as marker-only recurrences. Both the AUA and NCCN recommend surveillance as the preferred management for stage IA disease (pT1 without LVI).
A risk-adapted approach is used for patients with higher pathological stages or the presence of LVI. Those with pT2 or higher tumors or LVI have a relapse risk of 30-50%. Management options include surveillance with an understanding of the increased relapse risk, primary RPLND, or adjuvant chemotherapy consisting of one to two cycles of BEP (bleomycin, etoposide, cisplatin).
Primary RPLND involves a nerve-sparing retroperitoneal lymph node dissection that serves both as surgical staging and treatment. Approximately 70-75% of patients will have pathologic stage I disease (pN0) and are cured by surgery alone. The remaining 25-30% will have pathologic stage II disease (pN+) and may require adjuvant chemotherapy. Advantages of primary RPLND include definitive staging, avoidance of chemotherapy in the majority of patients, and removal of chemoresistant teratoma. Disadvantages include surgical morbidity and the risk of ejaculatory dysfunction if nerves are not spared. The choice between primary RPLND and surveillance for high-risk stage I disease remains controversial but is increasingly favored at high-volume centers.
Adjuvant chemotherapy with one to two cycles of BEP reduces relapse rates to less than 3%. This option is generally reserved for high-risk patients with LVI who decline surveillance or RPLND, although it exposes some patients with low-volume disease to chemotherapy toxicity unnecessarily.
---
## RPLND: Technique and Templates
The retroperitoneal lymphatic drainage follows the gonadal vessels, with primary landing zones differing by testicular side. For the right testis, lymph nodes are located in the interaortocaval, precaval, preaortic, and right paracaval regions. For the left testis, the primary nodes are in the left para-aortic, preaortic, and interaortocaval regions, with some crossover.
Modified template RPLND limits dissection to these primary landing zones to preserve sympathetic chains and postganglionic fibers responsible for antegrade ejaculation. The right template includes right paracaval, precaval, interaortocaval, and preaortic nodes, bounded laterally by the ureters, superiorly by the renal vessels, and inferiorly by the common iliac bifurcation. The left template includes left para-aortic, preaortic, and interaortocaval nodes, with similar anatomical boundaries.
The nerve-sparing technique focuses on identifying and preserving postganglionic sympathetic fibers from T12 to L3 and the hypogastric plexus below the aortic bifurcation. These nerves control antegrade ejaculation by mediating emission and bladder neck closure. Nerve-sparing RPLND preserves antegrade ejaculation in over 95% of cases, whereas full bilateral templates without nerve-sparing carry a 50-75% risk of retrograde ejaculation.
Robotic RPLND is an emerging approach gaining traction for both primary and post-chemotherapy cases. It offers magnified visualization, precise nerve identification, and reduced morbidity. However, its oncologic equivalence to open RPLND remains under investigation, and concerns exist regarding adequate template coverage and lymph node yield. Robotic RPLND is best performed at high-volume centers by experienced surgeons.
---
## Advanced Germ Cell Tumors (Stage II-III)
The International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification stratifies metastatic germ cell tumors based on clinical and laboratory parameters.
Good-risk seminoma includes any primary site without non-pulmonary visceral metastases, normal alpha-fetoprotein (AFP), any human chorionic gonadotropin (hCG), and any lactate dehydrogenase (LDH). Good-risk non-seminoma includes testicular or retroperitoneal primaries without non-pulmonary visceral metastases, AFP less than 1,000 ng/mL, hCG less than 5,000 IU/L, and LDH less than 1.5 times the upper limit of normal (ULN). Five-year survival rates are approximately 91% for seminoma and 92% for non-seminoma in this group.
Intermediate-risk seminoma is characterized by any primary site with non-pulmonary visceral metastases, normal AFP, any hCG, and any LDH. Intermediate-risk non-seminoma includes testicular or retroperitoneal primaries without non-pulmonary visceral metastases but with AFP between 1,000 and 10,000 ng/mL, hCG between 5,000 and 50,000 IU/L, or LDH between 1.5 and 10 times ULN. Five-year survival rates are 72% for seminoma and 80% for non-seminoma.
Poor-risk disease applies only to non-seminoma and includes mediastinal primary tumors, non-pulmonary visceral metastases (such as liver, bone, or brain), or very high tumor markers (AFP >10,000 ng/mL, hCG >50,000 IU/L, LDH >10 times ULN). The five-year survival rate in this group is about 48%.
| Risk Group | Seminoma Criteria | Non-Seminoma Criteria | 5-Year Survival |
|---|---|---|---|
| Good | Any site; no non-pulmonary visceral mets; normal AFP, any hCG/LDH | Testis/RP primary; no non-pulmonary visceral mets; AFP <1,000, hCG <5,000, LDH <1.5x ULN | Seminoma 91%; NSGCT 92% |
| Intermediate | Any site; non-pulmonary visceral mets; normal AFP, any hCG/LDH | Testis/RP primary; no non-pulmonary visceral mets; AFP 1,000-10,000, hCG 5,000-50,000, or LDH 1.5-10x ULN | Seminoma 72%; NSGCT 80% |
| Poor | Does not exist for seminoma | Mediastinal primary, or non-pulmonary visceral mets, or AFP >10,000, hCG >50,000, LDH >10x ULN | NSGCT 48% |
Chemotherapy regimens vary by risk category. Good-risk patients typically receive three cycles of BEP, consisting of bleomycin 30 units IV on days 1, 8, and 15; etoposide 100 mg/m² IV on days 1-5; and cisplatin 20 mg/m² IV on days 1-5, repeated every 21 days. Alternatively, four cycles of EP (etoposide and cisplatin) may be used if bleomycin is contraindicated due to pulmonary risk. Intermediate-risk patients receive four cycles of BEP. Poor-risk patients also receive four cycles of BEP as standard, with salvage regimens such as TIP (paclitaxel, ifosfamide, cisplatin), VeIP (vinblastine, ifosfamide, cisplatin), or high-dose chemotherapy with autologous stem cell transplant (HDCT/ASCT) reserved for incomplete responses.
Bleomycin pulmonary toxicity is the most feared complication, manifesting as dose-dependent pulmonary fibrosis, particularly at cumulative doses exceeding 400 units. Risk factors include age over 40, renal insufficiency, and exposure to high inspired oxygen fractions (FiO2) during surgery or anesthesia. Pulmonary function tests with diffusing capacity for carbon monoxide (DLCO) should be monitored before and during treatment. High FiO2 should be avoided during anesthesia and postoperatively, even years after bleomycin exposure. If bleomycin is contraindicated, EP x 4 is used for good-risk patients, and VIP (etoposide, ifosfamide, cisplatin) may substitute bleomycin in intermediate or poor-risk patients.
---
## Post-Chemotherapy Management
In seminoma patients, residual retroperitoneal masses measuring 3 cm or less are typically observed, as 90% represent necrosis or fibrosis. For masses larger than 3 cm, a PET/CT scan is performed at least six weeks after chemotherapy completion. A negative PET scan warrants observation, while a positive PET scan necessitates resection or biopsy. If viable seminoma is confirmed, additional chemotherapy or radiation may be indicated. Post-chemotherapy RPLND in seminoma is technically challenging due to desmoplastic reactions.
For non-seminoma patients with normalized tumor markers but residual masses, management depends on mass size. Residual masses of 1 cm or larger require post-chemotherapy RPLND (PC-RPLND). Pathology from PC-RPLND reveals necrosis or fibrosis in 40-50% of cases, teratoma in 35-40%, and viable germ cell tumor in 10-15%. Teratoma is chemoresistant and radioresistant, necessitating surgical removal to prevent growing teratoma syndrome. If viable germ cell tumor is found, two additional cycles of chemotherapy are administered. Patients with normalized markers and residual masses smaller than 1 cm are observed. If tumor markers remain elevated after chemotherapy, salvage chemotherapy is indicated, and surgery should not be performed due to the presence of viable chemosensitive disease.
PC-RPLND requires a full bilateral template dissection because post-chemotherapy anatomy is distorted. The procedure may involve en-bloc resection of adjacent structures such as the aorta (with grafting), inferior vena cava, or kidney. It carries higher morbidity than primary RPLND, and nerve-sparing is more challenging but may be possible. Given its complexity, PC-RPLND should be performed only at high-volume centers with experience exceeding 10 such procedures per year.
---
A treatment algorithm for stage I testicular cancer showing parallel pathways for seminoma and non-seminoma. Seminoma branches to surveillance (preferred), adjuvant carboplatin AUC7 (alternative), or adjuvant RT (historical, not recommended). Non-seminoma stratifies by risk (pT1 no LVI vs. pT2/LVI+) branching to surveillance, primary RPLND, or adjuvant BEP. 5-year relapse rates and CSS are annotated for each option. The IGCCCG classification for advanced disease is shown below with corresponding chemotherapy regimens (BEP x 3 vs. BEP x 4). Clinical algorithm format.
A diagram of the retroperitoneum showing RPLND templates for right-sided and left-sided testicular tumors. Anterior view of the aorta, IVC, renal vessels, ureters, and iliac bifurcation with the right template (paracaval, precaval, interaortocaval) and left template (para-aortic, preaortic, interaortocaval) color-coded. The sympathetic chain and postganglionic fibers responsible for ejaculation are illustrated with their course relative to the dissection boundaries. Nerve-sparing landmarks are labeled. Surgical anatomy illustration style.
A flowchart for post-chemotherapy management of non-seminoma GCT residual masses. Starting with post-chemo marker status: markers normalized → residual mass assessment (≥1 cm → PC-RPLND with pathology outcomes: necrosis/fibrosis, teratoma, viable GCT and their subsequent management; <1 cm → observe). Markers not normalized → salvage chemotherapy. For seminoma: residual ≤3 cm → observe; >3 cm → PET/CT at 6 weeks with PET-positive and PET-negative pathways. Clinical decision algorithm format with pathology distribution percentages.
---
## Clinical Pearls
Surveillance remains the preferred management strategy for both stage I seminoma and low-risk non-seminoma (pT1 without LVI), achieving cure rates exceeding 99% with timely salvage treatment upon relapse. Lymphovascular invasion is the most significant risk factor for relapse in stage I NSGCT, increasing relapse risk from approximately 15% to 30-50%, and often favors consideration of primary RPLND or adjuvant BEP chemotherapy. Teratoma is resistant to both chemotherapy and radiation, making surgical resection the only effective treatment; this underlies the rationale for post-chemotherapy RPLND in NSGCT patients with residual masses. Surgery should never be performed in patients with rising tumor markers after chemotherapy, as this indicates viable, chemosensitive disease requiring salvage chemotherapy first. Bleomycin pulmonary toxicity can be fatal; therefore, high inspired oxygen fractions must be avoided during any anesthesia, even years after exposure, and the anesthesiology team must be informed of prior bleomycin treatment. Post-chemotherapy RPLND is a complex, high-morbidity procedure best performed at high-volume referral centers, where outcomes correlate strongly with surgeon and center experience. PET/CT is valuable for evaluating post-chemotherapy residual masses in seminoma larger than 3 cm but has no established role in non-seminoma post-chemotherapy assessment.
---
## References
- Gilligan T, et al. AUA/ASCO Guideline: Testicular Cancer. J Urol. 2019;202(4):682-698
- International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification. J Clin Oncol. 1997;15(2):594-603
- Tandstad T, et al. One course of adjuvant BEP in clinical stage I non-seminoma mature and expanded results (SWENOTECA). Ann Oncol. 2014;25(11):2167-2172
- Oldenburg J, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline. Ann Oncol. 2022;33(4):362-375
- NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer, Version 1.2024